Cisco Systems, Inc. (NASDAQ:CSCO) has released emergency patches for two critical vulnerabilities in its Data Center Network Manager, which could allow attackers to take control of impacted systems. The Data Center Network Manager (DCNM) is Cisco’s network management platform for switches running on its network operating system (NX-OS), including Cisco Nexus Series switches. Overall, the networking giant patched four flaws that existed in the software on this platform: two critical, one high-severity and one medium-severity.
Cisco Systems, Inc. (NASDAQ:CSCO) shares ticked up 0.93% to finally closed at $56.60 in last active session.
CSCO’s distance from 20 day simple moving average is 2.43% and distance from 50-Day simple moving average is 2.63%.
Analyst’s mean target price for CSCO is $58.63 while analysts mean recommendation is 2.00. Stock value has moved between $40.14 – 58.35 in last one year. Stock has got OUTPERFORM rating from 10 of Thomson Reuters analysts, 11 given HOLD rating to the stock and 0 given UNDERPERFORM rating. Analyst’s mean target price for CSCO is $58.63 while analysts mean recommendation is 2.00.
Cisco Systems, Inc. (NASDAQ:CSCO) yearly performance is 33.84% and net profit margin is 25.80%. Annual EPS Growth of past 5 years is 3.00%. The current share price indicates that stock is -2.67% away from its one year high and is moving 40.62% ahead of its 52-week low.
On 26 June 2018, General Mills, Inc. (NYSE:GIS) shares slumped -4.45% and ultimately finalized to $51.31 in last traded day. Stock has got OUTPERFORM rating from 0 of Thomson Reuters analysts, 12 given HOLD rating to the stock and 2 given UNDERPERFORM rating. Analyst’s mean target price for GIS is $50.47 while analysts mean recommendation is 2.80.
At the movement Meridian Bioscience, Inc. (NASDAQ:VIVO) is under coverage by number of analysts. Buy rating has been given by 0 analysts to the company stock whereas 0 given UNDERPERFORM rating to stock and 3 given HOLD rating. The consensus recommendation by Thomson Reuters analysts is hold and their mean rating for the stock is 3.50 on scale of 1-5. Analysts mean target price for Meridian Bioscience, Inc. (NASDAQ:VIVO) is $10.67 while their mean recommendation is 3.50 (1=Buy, 5=sell).
If we look at stock performance in last active day trading, we see that stock has moved slumped -0.70% to end the day at $11.31. The current share price indicate that stock is -42.99% away from its one year high and is moving 5.01% ahead of its 52-week low.